News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Features How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts Michael O'Riordan May 23, 2017
News Daily News Trans Fat Ban Led to Tangible CVD Benefits, New York State Analysis Shows Michael O'Riordan April 12, 2017
News Daily News ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events Michael O'Riordan April 04, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Daily News Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint Michael O'Riordan February 03, 2017
News Features Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond Shelley Wood December 30, 2016
News Daily News PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk Michael O'Riordan December 01, 2016
News Daily News Nearly 40% of Diabetic Patients Not Treated With Statins: PINNACLE Registry Michael O'Riordan September 13, 2016
News Daily News Los Niveles Altos de Lípidos Dictados Genéticamente Parecen Proteger Frente a la Diabetes Tipo 2 Todd Neale August 04, 2016
News Daily News Genetically Dictated Higher Lipid Levels Seem to Protect Against Type 2 Diabetes Todd Neale August 04, 2016
News Daily News AstraZeneca Strives to Block Generic Crestor as Observers Call Foul Michael O'Riordan July 13, 2016
News Daily News Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings Michael O'Riordan July 12, 2016
News Daily News Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns Todd Neale January 18, 2016
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015
News Conference News ESC 2015 Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes Yael L. Maxwell September 01, 2015
News Industry News New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology August 20, 2015